NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the appointment of David Wambeke as Chief Business Officer, effective March 1, 2026. In conjunction with his appointment, Mr. Wambeke purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share, representing the closing price on February 27, 2026. This insider purchase demonstrates strong alignment with shareholders and confidence in the company's strategic direction.
Mr. Wambeke will lead NeuroOne's drug delivery program and collaborate with the executive team to advance clinical development and commercialization. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners to maximize the value of the company's drug delivery platform. He will also oversee investor relations and support strategic business development initiatives, including partnerships and other corporate transactions.
CEO Dave Rosa commented, 'David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution.' Mr. Wambeke previously served as Chief Business Officer at DiaMedica Therapeutics, where he led the expansion of a lead biologic into preeclampsia, establishing a first-in-pregnancy Phase 2 trial that delivered positive results. Prior to that, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army and was awarded the Purple Heart after being wounded in combat in Baghdad, Iraq.
Mr. Wambeke stated, 'I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment.' He noted that with four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. He believes even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation.
NeuroOne intends to use the net proceeds from the share sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. The shares sold to Mr. Wambeke were not registered under the Securities Act and were issued in a private transaction. Additionally, the company granted Mr. Wambeke an inducement stock option to purchase 500,000 shares under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan, with an exercise price of $0.6704 per share, vesting over four years. This grant was a material inducement for his acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. Its minimally invasive electrode technology platform includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.
